Y-mAbs Therapeutics (YMAB) Stock Highlights

10.41 | +3.07%

2024-11-23 04:23:49

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

Statistics

Range Today

9.93 10.49

Volume Today 253.9K

Range 1 Year

5.29 20.9

Volume 1 Year 80.14M

Range 3 Year

2.7 20.9

Volume 3 Year 312.78M

Range 10 Year

2.7 55.22

Volume 10 Year 473.4M

Highlights

Market Capitalization 693.96M (small)

Floating Shares 27.07M

Current Price 10.41

Price To Earnings -24.64

Price To Revenue 7.12

Price To Book 6.7

Earnings Per Share -0.56

Payout Ratio 0%

Performance

Latest +3.07%

1 Month -28.21%

3 Months -25.64%

6 Months -17.05%

1 Year +96.42%

3 Years -42.45%

5 Years -64.04%

10 Years -60.72%

Benchmarks

Market Capitalization

149 / 368

Gross Profits

59 / 278

Total Revenue

94 / 300

Total Rank

74 / 368

Free Cashflow

87 / 352

Performance 5 years

186 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.